canertinib dihydrochloride,
CI 980,
CI-980,
PD 183805,
PD-183805,
PD183805,
Canertinib dihydrochloride,
289499-45-2,
CI-1033,
Canertinib HCl,
CI 1033,
Canertinib (dihydrochloride),
UNII-ICJ93X8X90,
PD 183805,
Canertinib dihydrochloride [USAN],
PD-0183805,
ICJ93X8X90,
MFCD09954112,
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride,
N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide dihydrochloride,
Q-101362,
Q-200787,
CHEMBL545315,
Canertinib dihydrochloride (USAN),
2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride,
2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride,
2-Propenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-, hydrochloride (1:2),
N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride,
N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride,
C24H25ClFN5O3.2ClH,
Canertinib HCl,
Canertinib 2HCl,
Canertinib.2HCL,
CI-1033 dihydrochloride,
Canertinib(dihydrochloride),
AC1L4G5O,
PD-183805 dihydrochloride,
Canertinib dihydrochloride salt,
SCHEMBL2052123,
AOB6735,
DTXSID80183143,
BCP01902,
KS-00000FV0,
3516AH,
HY-10367A,
RS0031,
AKOS015924656,
AC-2414,
AN-6697,
CS-0263,
KIN0000080,
AK326128,
BC673861,
SC-23744,
SN-26606,
AB1004832,
LS-185636,
A3276,
AM20090674,
FT-0724289,
CI-1033, >=98% (HPLC),
A19399,
D03350,
W-5427,
Canertinib dihydrochloride; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride,
N-[4-(3-chloro-4-fluoro-anilino)-7-(3-morpholinopropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride,
N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride,
N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride,
N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride,
Canertinib,
Candesartan cilexetil,
Canertinibdihydrochloride,
cc-446,
PD-183805,
PD183805,
CI1033,
CI-103,
CID156413,
Canertinib dihydrochloride(CI 1033),
289499-45-2 (HCl salt),
ACN-040200,
C24-H25-Cl-F-N5-O3.2Cl-H,
C420268,
N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide,
267243-28-7,